Pershing Square threatens lawsuit to stop Allergan shopping spree
This article was originally published in Scrip
Executive Summary
Allergan's battle to remain independent in the face of a $50bn-plus buyout offer from Valeant Pharmaceuticals has gone from bitter to ugly with a new legal threat from the Botox and Restasis marketer's largest shareholder Pershing Square Capital Management.